Abstract

The LncRNA my-heart (Mhrt) and the chromatin remodeler Brg1 inhibit each other to respectively prevent or favor the maladaptive α-myosin-heavy-chain (Myh6) to β-myosin-heavy-chain (Myh7) switch, so their balance crucially guides the outcome of cardiac remodeling under stress conditions. Even though triiodothyronine (T3) has long been recognized as a critical regulator of the cardiac Myh isoform composition, its role as a modulator of the Mhrt/Brg1 axis is still unexplored. Here the effect of T3 on the Mhrt/Brg1 regulatory circuit has been analyzed in relation with chromatin remodeling and previously identified T3-dependent miRNAs. The expression levels of Mhrt, Brg1 and Myh6/Myh7 have been assessed in rat models of hyperthyroidism or acute myocardial ischemia/reperfusion (IR) treated with T3 replacement therapy. To gain mechanistic insights, in silico analyses and site-directed mutagenesis have been adopted in combination with gene reporter assays and loss or gain of function strategies in cultured cardiomyocytes. Our results indicate a pivotal role of Mhrt over-expression in the T3-dependent regulation of Myh switch. Mechanistically, T3 activates the Mhrt promoter at two putative thyroid hormone responsive elements (TRE) located in a crucial region that is necessary for both Mhrt activation and Brg1-dependent Mhrt repression. This newly identified T3 mode of action requires DNA chromatinization and is critically involved in mitigating the repressive function of the Brg1 protein on Mhrt promoter. In addition, T3 is also able to prevent the Brg1 over-expression observed in the post-IR setting through a pathway that might entail the T3-mediated up-regulation of miR-208a. Taken together, our data evidence a novel T3-responsive network of cross-talking epigenetic factors that dictates the cardiac Myh composition and could be of great translational relevance.

Highlights

  • IntroductionDespite available interventions improving patient prognosis, sustained pathological hypertrophy is still one of the main risk factors for heart failure and cardiovascular mortality in humans [1]

  • The T3-dependent regulation of the Mhrt/Brahma-related gene 1 (Brg1) axis appears to be a novel cardioprotective mechanism that contributes to explain why Thyroid hormones (THs) treatment is associated with the reversal of pathological cardiac hypertrophy in favor of more physiological cardiac growth [10]

  • We propose a model whereby T3 affects a network of cross-talking epigenetic modifiers that act at the myosin heavy chain (MHC) locus and regulate each other to maintain the proper MHC fiber composition of the adult heart

Read more

Summary

Introduction

Despite available interventions improving patient prognosis, sustained pathological hypertrophy is still one of the main risk factors for heart failure and cardiovascular mortality in humans [1]. The evolution of pathological hypertrophy is due to a maladaptive down-regulation of the adult isoforms of cardiac muscle proteins including the alpha myosin heavy chain (α-MHC) and a concomitant up-regulation of the fetal genes such as the beta myosin heavy chain (β-MHC), atrial natriuretic peptide (ANF), and brain natriuretic peptide (BNP) [2]. A long non-coding RNA (lncRNA), termed Myheart (Mhrt), was demonstrated to protect the heart against adverse remodeling by inhibiting the maladaptive alpha to beta myosin heavy chain (MHC). Mhrt transcripts sequester the ATP-dependent Brahma-related gene 1 (Brg1) protein.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call